Early-Onset and Robust Amyloid Pathology in a New Homozygous Mouse Model of Alzheimer's Disease
Authors:
Open Access
- 20 November 2009
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 4 (11) , e7931
Abstract
Transgenic mice expressing mutated amyloid precursor protein (APP) and presenilin (PS)-1 or -2 have been successfully used to model cerebral β-amyloidosis, one of the characteristic hallmarks of Alzheimer's disease (AD) pathology. However, the use of many transgenic lines is limited by premature death, low breeding efficiencies and late onset and high inter-animal variability of the pathology, creating a need for improved animal models. Here we describe the detailed characterization of a new homozygous double-transgenic mouse line that addresses most of these issues. The transgenic mouse line (ARTE10) was generated by co-integration of two transgenes carrying the K670N/M671L mutated amyloid precursor protein (APPswe) and the M146V mutated presenilin 1 (PS1) both under control of a neuron-specific promoter. Mice, hemi- as well as homozygous for both transgenes, are viable and fertile with good breeding capabilities and a low rate of premature death. They develop robust AD-like cerebral β-amyloid plaque pathology with glial inflammation, signs of neuritic dystrophy and cerebral amyloid angiopathy. Using our novel image analysis algorithm for semi-automatic quantification of plaque burden, we demonstrate an early onset and progressive plaque deposition starting at 3 months of age in homozygous mice with low inter-animal variability and 100%-penetrance of the phenotype. The plaques are readily detected in vivo by PiB, the standard human PET tracer for AD. In addition, ARTE10 mice display early loss of synaptic markers and age-related cognitive deficits. By applying a γ-secretase inhibitor we show a dose dependent reduction of soluble amyloid β levels in the brain. ARTE10 mice develop a cerebral β-amyloidosis closely resembling the β-amyloid-related aspects of human AD neuropathology. Unifying several advantages of previous transgenic models, this line particularly qualifies for the use in target validation and for evaluating potential diagnostic or therapeutic agents targeting the amyloid pathology of AD.Keywords
This publication has 66 references indexed in Scilit:
- Neuronal IGF‐1 resistance reduces Aβ accumulation and protects against premature death in a model of Alzheimer's diseaseThe FASEB Journal, 2009
- Spatial relationship between synapse loss and β‐amyloid deposition in Tg2576 miceJournal of Comparative Neurology, 2006
- Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathologyEMBO Reports, 2006
- Early Changes in Behavior Deficits, Amyloid β-42 Deposits and MAPK Activation in Doubly Transgenic Mice Co-expressing NSE-Controlled Human Mutant PS2 and APPswCellular and Molecular Neurobiology, 2005
- Age-progressing cognitive impairments and neuropathology in transgenic CRND8 miceBehavioural Brain Research, 2005
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004
- Alzheimer's Disease Is a Synaptic FailureScience, 2002
- Progressive and gender-dependent cognitive impairment in the APPSW transgenic mouse model for Alzheimer’s diseaseBehavioural Brain Research, 1999
- Amyloid Phenotype Characterization of Transgenic Mice Overexpressing both Mutant Amyloid Precursor Protein and Mutant Presenilin 1 TransgenesNeurobiology of Disease, 1999
- Disappearance of actin‐binding protein, drebrin, from hippocampal synapses in alzheimer's diseaseJournal of Neuroscience Research, 1996